Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Due to their interactions with the neoplasm, platelets undergo various proteomic and transcriptomic modifications, resulting in the development of what is known as the "Tumor-Educated Platelets (TEPs) phenotype". Consequently, in addition to their suitability for Liquid Biopsy (LB) applications, they play a pivotal role in the malignancy by communicating with Circulating Tumor Cells (CTCs), Tumor Microenvironment (TME), and the tumor itself through multiple mechanisms and at multiple levels, ultimately promoting the metastasis of cancer. Therefore, this Systematic Review of MEDLINE and the Cochrane Library present in-depth insights into these phenomena, with the aim of enhancing the understanding of the complex interplay between TEPs and Non-Small Cell Lung Cancer (NSCLC). This endeavor serves to provide context and drive medical research efforts, which are increasingly focused on developing novel diagnostic and therapeutic technologies that leverage the specific binding of these platelets to the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863699 | PMC |
| http://dx.doi.org/10.1016/j.jlb.2024.100136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.
Int J Mol Sci
August 2025
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with a growing incidence and significant molecular heterogeneity that challenges traditional diagnostic and management paradigms. While histopathological assessment remains the gold standard for diagnosis, emerging liquid biopsy technologies provide promising non-invasive alternatives for tumor detection, molecular profiling, and disease monitoring. This review comprehensively explores the current landscape and clinical utility of liquid biopsy analytes-including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular RNAs, and exosomes-in the context of EC.
View Article and Find Full Text PDFNavigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions.
Int J Mol Sci
August 2025
Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Cagliari, Italy.
Liquid biopsy has emerged as a valuable tool for the detection and monitoring of colorectal cancer (CRC), providing minimally invasive insights into tumor biology through circulating biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). Additional biomarkers, including tumor-educated platelets (TEPs) and exosomal RNAs, offer further potential for early detection and prognostic role, although ongoing clinical validation is still needed. This review summarizes the current evidence on the diagnostic, prognostic, and predictive capabilities of liquid biopsy in both metastatic and non-metastatic CRC.
View Article and Find Full Text PDFRecent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer.
Future Oncol
September 2025
Department of Public Health, University of Naples Federico II, Naples, Italy.
Lung Cancer (LC) remains the leading cause of cancer-related mortality. While Tissue Biopsy (TB) remains the gold standard for molecular profiling, its invasiveness and inability to provide real-time monitoring have led to the adoption of Liquid Biopsy (LB) as a minimally invasive alternative. By analyzing different circulating analytes such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), and Tumor-Educated Platelets (TEPs), LB offers a dynamic approach to assessing tumor heterogeneity, Minimal Residual Disease (MRD), and treatment resistance.
View Article and Find Full Text PDFNovel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood.
J Liq Biopsy
September 2025
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131, Naples, Italy.
The liquid biopsy (LB) represents a minimally invasive method for cancer screening that has been introduced in clinical practice for over a decade and that can accelerate treatment response assessment. LB allows the analysis of tumor cells or tumor-derived products (e.g.
View Article and Find Full Text PDFTumor-educated platelets: A new field in breast cancer diagnosis.
Clin Chim Acta
September 2025
Clinical Laboratory, Weifang People's Hospital, Shandong Second Medical University, Weifang 261000 Shandong, China. Electronic address:
Tumor-educated platelets (TEPs) represent a novel approach in liquid biopsy, offering new perspectives for diagnosing, treating, and monitoring breast cancer. Unlike traditional histopathological biopsies-the current diagnostic gold standard-TEP-based detection is minimally invasive, requiring only peripheral blood samples and overcoming limitations of repeated invasive procedures. TEPs reflect a dynamic interplay between tumor cells, platelets, and the tumor microenvironment: tumors alter platelet expression profiles while TEPs provide comprehensive molecular information about tumor genetics.
View Article and Find Full Text PDF